Docetaxel - an agent worth pursuing in NSCLC

    loading  Checking for direct PDF access through Ovid

Abstract

Docetaxel [Taxotere®; Rhône-Poulenc Rorer; phase II] demonstrated the highest antitumour response rate ever reported for any single agent tested against nonsmall cell lung cancer (NSCLC) in trials at the Memorial Sloan-Kettering Cancer Center, New York, US. These promising results were presented at a symposium sponsored by Rhône-Poulenc Rorer which was held during the European Congress of Clinical Oncology (ECCO) in Jerusalem, Israel, in November.

Related Topics

    loading  Loading Related Articles